Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Another study confirms detrimental effects of delaying hepatitis C treatment

Deferring antiviral therapy for hepatitis C until a person progresses to advanced liver disease has clear drawbacks including lower treatment effectiveness and an increased risk of clinical

Published
05 May 2015
By
Liz Highleyman
When a short course of sofosbuvir/ledipasvir fails, some people can be cured of hepatitis C with a double treatment duration

More than 70% of people with chronic genotype 1 hepatitis C who did not achieve a sustained virological response when treated with sofosbuvir/ledipasvir (Harvoni) for 8 or 12

Published
01 May 2015
By
Liz Highleyman
Sofosbuvir-based treatment safe and effective in advanced kidney disease

Sofosbuvir-based direct-acting antiviral therapy for hepatitis C can be used safely and effectively in people with very advanced kidney disease, including people on dialysis, according to the

Published
30 April 2015
By
Keith Alcorn
Merck's grazoprevir/elbasvir combo cures 99% of hepatitis C in chronic kidney disease

The once-daily combination of grazoprevir and elbasvir cured hepatitis C in 99% of people with advanced chronic kidney disease, researchers reported at the International Liver Congress last

Published
28 April 2015
By
Keith Alcorn
Sofosbuvir plus pegylated interferon/ribavirin is highly effective for people with hard-to-treat genotype 3 hepatitis C

A throwback regimen of sofosbuvir (Sovaldi), ribavirin and pegylated interferon taken for 12 weeks cured 93% of people with hepatitis C virus (HCV) genotype 3 – substantially

Published
28 April 2015
By
Liz Highleyman
Sofosbuvir, daclatasvir and ribavirin cures hepatitis C for most people with advanced cirrhosis or liver transplants

An interferon-free regimen of sofosbuvir, daclatasvir and ribavirin for 12 weeks produced sustained response rates of 83% for people with hepatitis C virus (HCV) who had advanced

Published
28 April 2015
By
Liz Highleyman
New EASL guidelines prioritise interferon-free hepatitis C treatment

The European Association for the Study of the Liver (EASL) released its latest hepatitis C treatment guidelines at the 50th International Liver Congress which took place last

Published
27 April 2015
By
Liz Highleyman
Alcohol misuse the strongest predictor of severe liver damage and death in French people with hepatitis C

People with hepatitis C have a much greater risk of liver-related hospitalisation or death if they have an alcohol use disorder or another serious comorbidity such as

Published
27 April 2015
By
Keith Alcorn
Expanded vaccination and treatment could help eliminate hepatitis B worldwide

While universal infant hepatitis B virus (HBV) vaccination has already led to major advances in reducing new infections in some settings, further expansion of prevention and treatment

Published
25 April 2015
By
Liz Highleyman
Grazoprevir/elbasvir highly effective in treatment-experienced and HIV-coinfected hepatitis C patients

The combination of grazoprevir and elbasvir without ribavirin is highly effective in curing hepatitis C infection in 12 weeks in some groups of treatment-experienced patients and in

Published
25 April 2015
By
Keith Alcorn

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.